Exhibit 10.5
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
ARS Pharmaceuticals Operations, Inc.
11682 El Camino Real, Suite 300 San Diego, CA 92130
To:
ALK-Abelló, Inc.
135 Route 202/206 Suite #16 Bedminster, New Jersey 07921 Attention: President
Re: Side Letter to Co-Promotion Agreement, dated as of May 2, 2025, as amended October 23, 2025, and March 3, 2026 (as amended, the “Agreement”), by and between ARS Pharmaceuticals Operations, Inc. (“ARS”) and ALK-Abelló, Inc. (“ALK”).
Dear ALK:
This letter agreement (the “Side Letter”) is entered into as of August 31, 2026 (the “Side Letter Effective Date”), by and between ARS and ALK (together, the “Parties”) in connection with the Agreement. Capitalized terms used but not otherwise defined herein shall have the respective meanings given in the Agreement.
WHEREAS, the Parties desire to provide ARS with [***], with an adjusted Base Fee applicable for [***]; and
WHEREAS, [***].
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants set forth herein, the Parties agree as follows:
Except for the consent set forth above, the existing terms and conditions of the Agreement shall continue to have full force and effect.
The governing law and dispute resolution provisions set forth in Sections 12.1 and 12.2, respectively, of the Agreement shall apply to this Letter Agreement, mutatis mutandis.